1. Acute alertness-promoting effects of a novel histamine subtype-3 receptor inverse agonist in healthy sleep-deprived male volunteers.
- Author
-
Iannone R, Palcza J, Renger JJ, Calder N, Cerchio K, Gottesdiener K, Hargreaves R, Dijk DJ, Boyle J, and Murphy MG
- Subjects
- Adolescent, Adult, Cross-Over Studies, Double-Blind Method, Humans, Male, Middle Aged, Sleep Deprivation physiopathology, Sleep Stages drug effects, Sleep Stages physiology, Time Factors, Wakefulness physiology, Young Adult, Drug Inverse Agonism, Histamine Agonists pharmacology, Histamine Agonists therapeutic use, Receptors, Histamine H3 physiology, Sleep Deprivation drug therapy, Wakefulness drug effects
- Abstract
The alertness-promoting effect of MK-0249 (10 or 50 mg), a histamine subtype-3 receptor (HRH3) inverse agonist (IA), was evaluated in the stimulant reference sleep deprivation model (SRSDM) using a double-blind, double-dummy, placebo- and modafinil- (200 mg) controlled, four-period crossover design in 24 healthy young men. The two primary hypotheses were related to sleep latency (first appearance of one epoch of stage 2, 3, or 4 or REM sleep, as detected using polysomnography (PSG)) at 8:00 AM on day 2. Statistically significant increases in sleep latency were observed in association with the use of modafinil 200 mg (9.07 min; P < 0.0001), MK-0249 50 mg (5.17 min; P = 0.008), and MK-0249 10 mg (5.45 min; P = 0.005) at the maintenance of wakefulness test (MWT) at 8:00 AM. Sleep latency was higher when averaged over all MWT time points (P < 0.0001 for modafinil and for both doses of MK-0249). The alertness-promoting effect with the use of MK-0249 in the SRSDM suggests that HRH3 IAs may be effective in disorders involving excessive somnolence.
- Published
- 2010
- Full Text
- View/download PDF